Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced the successful completion of the U.S. rollout of the Adaptive Nomogram technology used on its Aurora Xi Plasmapheresis System across BioLife Plasma Services’ network of plasma donation centers. The implementation, which began in March 2025 in a phased approach, has been completed ahead of schedule, marking a significant milestone in helping plasma centers advance plasma collection efficiency and donation personalization.
Health Technology Insights: Helia Care Expands Network, Leads in Healthcare Procurement Technology
“We are proud to see our Adaptive Nomogram technology fully deployed at BioLife Plasma Services’ donation centers and delivering measurable impact while meeting BioLife’s expectations,” said Dr. Christian Hauer, President, MedTech at Fresenius Kabi.
The Adaptive Nomogram technology, used with Fresenius Kabi’s Aurora Xi Plasmapheresis System, optimizes plasma collection by tailoring donation volumes based on each donor’s individual body attributes. This data-driven approach enables more personalized and efficient plasma collection, supporting both donor safety and the sustainability of the plasma supply.
Health Technology Insights: HealthTree Expands EHR Connections with Flatiron and CareSpace
“We are proud to see our Adaptive Nomogram technology fully deployed at BioLife Plasma Services’ donation centers and delivering measurable impact while meeting BioLife’s expectations,” said Dr. Christian Hauer, President, MedTech at Fresenius Kabi. “This innovation brings a new level of personalization to plasma donations, helping our customers enhance efficiency and strengthen the sustainability of the plasma supply that is essential for lifesaving therapies.”
The nationwide rollout at BioLife Plasma Services’ donation centers began in March 2025 with pilot centers and was executed in a strategic, phased manner to ensure a smooth integration process while maintaining donor and plasma safety.
“Completing the rollout of this technology ahead of schedule reflects the thoughtful and phased approach taken that allowed us to avoid any business disruption while improving operational efficiency and continuing to maintain the safety of our plasma donors,” said Hema Tallman, Senior Vice President and Global Head of BioLife Plasma Services. “Working closely with Fresenius Kabi on this implementation has enabled us to strengthen our plasma supply and continue providing people in need with the life-sustaining and lifesaving medicines that BioLife produces from plasma.”
Health Technology Insights: OMRON Invests Again in Tricog Health for AI Cardiac Care
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
